Step 6: Treatment Success--Suppressed Viral Load
Active Resources: 36
Reports
-
11/1/2017
-
4/15/2015
-
6/19/2014
-
4/11/2014
Antiretroviral Guidelines
-
10/27/2017
Online Training
-
10/20/2017
-
8/23/2017
Webinars
-
6/8/2016
-
6/17/2015
-
3/13/2014
Toolkits
-
5/17/2016
-
10/30/2015
-
10/8/2015
-
7/31/2014 (reviewed: 2/12/2018)
-
2/19/2014
Image Library
-
4/6/2016
Primary Care Guidelines
-
11/9/2015
Charts, Tables & Posters
-
9/4/2015
-
7/1/2015
-
1/28/2015
-
8/22/2014
-
6/1/2013 (reviewed: 1/11/2017)
Slide Sets
-
8/11/2015
-
12/22/2014 (reviewed: 7/17/2015)
-
1/15/2014
Pocket Guides
-
4/1/2015
Manuals
-
2/4/2015
-
11/1/2013
-
8/1/2013
Articles & Bibliographies
-
10/9/2014
-
9/19/2014
-
4/21/2014
-
4/21/2014
-
3/6/2014
Videos
-
7/17/2014
Patient Information
-
7/7/2014
Archive Resources: 10
Clinical Reference Tools
-
9/10/2015
Reports
-
11/12/2014
Pocket Guides
-
4/30/2013
-
6/1/2009
Patient Information
-
8/6/2012
Slide Sets
-
7/1/2012
Fact Sheets
-
7/1/2012
Antiretroviral Guidelines
-
3/5/2012
Self-Study Materials
-
1/1/2010
Curricula
-
9/1/2009
Articles: 6
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
in+care Campaign Update: The Results are In
National Quality Center (NQC) has completed its evaluation of the in+care Campaign -- the largest HIV quality improvement initiative carried out at the national level. We are pleased to announce that the Campaign demonstrated significant improvements in national retention and viral load...
-
Adult and Adolescent Guidelines: Major Changes
The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.
Efavirenz/TDF/FTC (Atripla) has... -
Some Thoughts on Building Capacity for the AETC Practice Transformation Projects
While there are many unknowns about exactly what the AETCs will look like with the start of the new grant cycle later this year, one thing we do know is that Practice Transformation (PT) and Practice Facilitation will be a part of the work. In fact about 40% of AETC resources will be devoted to...
-
Two New Boosted-PI Coformulations
Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:
Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...
-
New Fixed-Dose Combination Pill: Dolutegravir + Abacavir + Lamivudine
The FDA has approved the coformulation of the integrase inhibitor dolutegravir (50 mg) with the NRTIs abacavir (600 mg) and lamivudine (300 mg); its brand name is Triumeq. Triumeq is the first single-pill combination that does not include tenofovir.
Dosing is...
| Day | Title |
|---|---|
|
6/1 |
|
|
12/2 |
| Day | Title |
|---|---|
|
3/4 |
CROI 2018: Boston
Event type: Conferences & Events
|
|
10/23 |